Ethical Oncology Science S.p.A.'s investors are in line for at least 7x on their money based solely on the $200 million in upfront cash and stock that Clovis Oncology Inc. (NASDAQ:CLVS) is paying for the cancer company.

Sofinnova Partners' Antoine Papiernik said his firm seeded EOS in 2007 based on the firm's relationship with the management team, which had founded and sold another portfolio cancer play, Novuspharma S.p.A., to Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC).